It is almost 50 years since MEA was first developed, however, the power of this technology in toxicology testing has only just been realised due to the introduction of the multi-well MEA allowing for its utility in high throughput
analysis.
In this whitepaper, we focus on:
- the current challenges within the pharmaceutical industry in terms of toxicology prediction
- how companies are addressing these challenges using human relevant cell-based models
- an in-depth evaluation of microelectrode array (MEA) and its key role in in vitro cardiotoxicity and neurotoxicity toxicology testing
Read our whitepaper to learn more!